Expression and significance of P53 protein and MDM-2 protein in human gliomas

Chinese Medical Journal

Volumn 124, Issue 16, 2011, Pages 2530-2533

  Wang, An Liu ^a   Liu, Zhao Xia ^a   Li, Guang ^a   Zhang, Li Wei ^b  

^a Department of Pathology ^*  (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; MDM 2 protein; P53 protein

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; AGED; ARTICLE; CANCER GRADING; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GENE OVEREXPRESSION; GLIOMA; HEAD INJURY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052020009     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.16.024     Document Type: Article

References (14)

1. Korkolopoulou P, Christodoulou P, Kouzelis K, Hadjiyannakis M, Priftis A, Stamoulis G, et al. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer 1997; 75: 1269-1278.
2. Fulci G, Ishii N, Van Meir EG. P53 and brain tumors: from gene mutations to gene therapy. Brain Pathol 1998; 8: 599-613.
3. Hede SM, Nazarenko I, Nistér M, Lindström MS. Novel perspectives on p53 function in neural stem cells and brain tumors. Oncology 2011; 2011: 852970.
4. Tsuiki H, Nishi T, Takeshima H, Yano S, Nakamura H, Makino K, et al. Single nucleotide polymorphism 309 affects murin-double-minute 2 protein expression but not glioma tumorigenesis. Neurol Med Chir (Tokyo) 2007; 47: 203-208.
5. Finlay CA, Hinds PW, Levin AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-1093.
6. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679.
7. Brady CA, Attardi LD. P53 at a glance. J Cell Sci 2010; 123: 2527-2532.
8. Ranuncolo SM, Varela M, Morandi A, Lastiri J, Christiansen S, Bal de Kier et al. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas. J Neurooncol 2004; 68: 113-121.
9. Günther T, Schneider-Stock R, Häckel C, Kasper HU, Pross M, Hackelsberger A, et al. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol 2000; 13: 621-626.
10. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010; 24: 1580-1589.
11. Ichimura K, Bolin MB, Goike HM, Schmidt EE, Moshref A, Collins VP. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res 2000; 60: 417-424.
12. Kamiya M, Nakazato Y. The expression of p73, p21 and MDM2 proteins in gliomas. J Neurooncol 2002; 59: 143-149.
13. Schiebe M, Ohneseit P, Hoffmann W, Meyermann R, Rodemann HP, Bamberg M. Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors. J Neurooncol 2000; 49: 197-203.
14. Chen Q, Hung FC, Fromm L, Overbeek PA. Induction of cell cycle entry and cell death in postmitotic lens fiber cells by overexpression of E2F1 or E2F2. Invest Ophthalmol Vis Sci 2000; 41: 4223-4231.